Multicenter trial of the safety and efficacy of Certican [everolimus] in pediatric de novo renal transplant patients.

Trial Profile

Multicenter trial of the safety and efficacy of Certican [everolimus] in pediatric de novo renal transplant patients.

Completed
Phase of Trial: Phase III

Latest Information Update: 27 Feb 2017

At a glance

  • Drugs Everolimus (Primary)
  • Indications Renal transplant rejection
  • Focus Adverse reactions
  • Acronyms RAD351
  • Sponsors Novartis; Novartis Pharmaceuticals
  • Most Recent Events

    • 29 Nov 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top